Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19

Frontiers in Medicine

article

Flavio A. Cadegiani¹  Carlos G. Wambier³  Andy Goren⁴ 

[1] Department of Endocrinology, Federal University of São Paulo;Corpometria Institute;Department of Dermatology, Warren Alpert Medical School of Brown University, United States;Applied Biology Inc., United States

关键词: COVID-19;    SARS-CoV-2;    coronavirus;    pandemic;    spironolactone;    ARDS (acute respiratory distress syndrome);    androgen receptor antagonist;    TMPRSS2;   

DOI  :  10.3389/fmed.2020.00453

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

At the onset of the COVID-19 pandemic, mortality following infection of severe acute respiratory coronavirus (SARS-CoV-2) was thought to be solely associated with aging and pre-existing conditions; however, as the pandemic ensued, several large scale epidemiological observations eluded to additional atypical risk factors, particularly hypertension, obesity, and male gender (1–11).

【 授权许可】

CC BY